Bugworks secures funding from US Government's Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats
"We are very delighted to collaborate with DTRA and through them get the opportunity of working with intra-government agencies within the United States department of Defense, to advance BWC0977 as a potential single-stop solution against the most critical pathogens implicated in biothreats," added Anand Anandkumar, CEO of Bugworks.
ICMR study shows COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well
Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN®; Demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe COVID-19 disease
“We understand India’s needs,” says the US Government on vaccine’s raw material supply issues
The US Government responds to Serum’s request for allowing raw material and ingredients for Covid-19 vaccines. Mr Adar Poonawalla, CEO, Serum Institute of India (SII) had requested the US President Biden through a tweet asking the US to lift the embargo of raw material exports out of the US to ramp up vaccine production.